Detailseite
Projekt Druckansicht

Die Rolle des NLRP3-Inflammasoms im zentralen Nervensystem am Beispiel der sterilen Neuroinflammation beim Cryopyrin-assoziierten periodischen Fiebersyndrom

Antragstellerin Dr. Elisabeth Schuh
Fachliche Zuordnung Molekulare und zelluläre Neurologie und Neuropathologie
Molekulare Biologie und Physiologie von Nerven- und Gliazellen
Förderung Förderung von 2019 bis 2023
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 421414975
 
Erstellungsjahr 2023

Zusammenfassung der Projektergebnisse

Missense mutations in the PLCg2 gene can cause autoinflammation, antibody deficiency and immune dysregulation (APLAID). In vivo studies in existing PLCg2 mouse models are limited by the fact that the inflammatory disease phenotype does not transfer to the C57BL/6 background. Therefore, it has been challenging to validate in vitro studies linking autoinflammation in APLAID to the NLRP3 inflammasome. By generating a new mouse model carrying a human APLAID mutation (S707Y) we circumvented this problem and found to our surprise that the inflammatory infiltrates in skin, lung and gut were only partially ameliorated after removing inflammasome function via the deletion of caspase-1. Also, deleting IL-6 and TNF did not fully prevent APLAID mutant mice from autoinflammation. Overall, these findings are in accordance with poor treatment response for APLAID patients following treatments that block IL-1 or TNF. Further cytokine analysis revealed increased G-CSF levels as the most distinct feature in APLAID mice and patients. Treatment with an anti-G-CSF antibody completely suppressed clinical symptoms in mice with established APLAID in vivo, while immunodeficiency in the blood remained unaltered. APLAID mice were also fully rescued following bone marrow transplantation from healthy donors, associated with normalized G-CSF levels. To date, monogenic autoinflammatory diseases have predominantly been associated with activation of the inflammasome, type I interferons, or the NF- kB driven cytokines TNF and IL-6. Therefore, APLAID may represent the first in a new category of G-CSF driven autoinflammatory disease, for which targeted therapy is now conceivable.

Projektbezogene Publikationen (Auswahl)

 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung